Earnings results for FibroGen (NASDAQ:FGEN)
FibroGen, Inc is expected* to report earnings on 03/01/2021 after market close. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.29. The reported EPS for the same quarter last year was $-1.12.
Analyst Opinion on FibroGen (NASDAQ:FGEN)
7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $59.67, predicting that the stock has a possible upside of 19.26%. The high price target for FGEN is $92.00 and the low price target for FGEN is $40.00. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of “Hold.”
FibroGen has received a consensus rating of Hold. The company’s average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $59.67, FibroGen has a forecasted upside of 19.3% from its current price of $50.03. FibroGen has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: FibroGen (NASDAQ:FGEN)
FibroGen does not currently pay a dividend. FibroGen does not have a long track record of dividend growth.
Insiders buying/selling: FibroGen (NASDAQ:FGEN)
In the past three months, FibroGen insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,330,479.00 in company stock. Only 3.39% of the stock of FibroGen is held by insiders. 75.05% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of FibroGen (NASDAQ:FGEN
Earnings for FibroGen are expected to grow in the coming year, from ($1.72) to ($0.78) per share. The P/E ratio of FibroGen is -19.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of FibroGen is -19.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. FibroGen has a P/B Ratio of 8.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here